NORD writes PhRMA
Executive SummaryNational Organization for Rare Disorders criticizes Pharmaceutical Research & Manufacturers of America for ads suggesting that without drug patents research on rare diseases would decline. "The exclusivity provision of the Orphan Drug Act precludes competition for seven years with a higher degree of certainty [than patents], and this has influenced hundreds of companies to invest in orphan drug research and development," NORD says in June 6 letter...
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.